Safety and Efficacy of OncoTherad Nano-immunotherapy in Patients with Non-Muscle Invasive Bladder Cancer

Autor(es)

Alonso, J. C. C. ; Maciel, M. C. ; Ferrari, H. A. ; Goncalves, J. M. ; Sasaki, B. R. S. ; Cintra, A. A. ; Duran, N. ; Billis, A. ; Favaro, W. J. ; IOP Publishing

• Tipo de documento: Artigo Científico
• Fonte: Journal of Physics: Conference Series; v. 1953, p. 10-pg., 2021-01-01.

Resumo

The new modalities for treating patients with non-muscle invasive bladder cancer (NMIBC) for whom Bacillus Calmette-Guerin (BCG) has failed or is contraindicated are recently increasing due to the development of new drugs. In this scenario, a new perspective is represented by OncoTherad nano-immunotherapy. We carried out a prospective, single-center (Municipal Hospital of Paulinia, S (a) over tildeo Paulo, Brazil), single-arm phase I/ II study (Clinical Trial: RBR-6swqd2) in 29 (18 male, 11 female) patients with BCG-refractory, relapsed or intolerant NMIBC (>= 1 previous course of BCG therapy). The median age of the 29 patients and follow-up were 65 years (range 34-96) and 24 months, respectively. OncoTherad treatment showed complete response of 79.3% and recurrence-free survival of 22.2 months at 24-month follow-up. Regarding toxicity, 62.1% of adverse events were Grade 1 or 2. The most commonly reported treatment-related adverse events were dysuria, cystitis, pruritus, rash, arthralgia and fatigue. Also, this study demonstrated an important effect of activation of the Toll-like Receptor 4 (TLR4) signaling pathway triggered by OncoTherad in the formation and organization of primary lymphoid follicles in most patients at 24-months follow-up, which may be related to antitumor and immunoprotective effects from this immunotherapy in bladder tissue. In conclusion, OncoTherad nanoimmunotherapy seems a safe and effective treatment option for BCG-relapsed and/ or intravesical chemotherapy-relapsed NMIBC patients and may provide benefit for preventing tumor recurrence. (AU)

• Processo FAPESP: 18/10052-1 - Novas Abordagens Terapêuticas para o Câncer de Bexiga Não-Músculo Invasivo (CBNMI): Uso Intravesical do Modificador de Resposta Biológica OncoTherad e Sua Associação com o Plasma Rico em Plaquetas (PRP)
• Beneficiário: Wagner José Fávaro
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 20/03419-6 - Efeitos terapêuticos e toxicológicos da imunoterapia com OncoTherad (MRB-CFI-1) em pacientes com câncer de bexiga não-músculo invasivo recidivado não responsivo à terapia com Bacillus Calmette-Guérin (BCG)
• Beneficiário: Wagner José Fávaro
• Modalidade de apoio: Auxílio à Pesquisa - Regular